Trial intelligence / Profile preview

Cabazitaxel versus best supportive care in platinum-pretreated advanced or metastatic transitional cell carcinoma

2012-002552-16Phase 2Completed

Sponsor: University Hospitals Birmingham
Start: Oct 2012
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) and Glandular Variant Urothelial Carcinoma comparing Cabazitaxel with Best supportive care (2 arms). Primary endpoint: Overall response rate. Started Oct 2012; status: completed.

Drugs

cabazitaxel

Conditions

transitional cell carcinoma (TCC)Glandular Variant Urothelial Carcinoma

Beyond the preview

Go deeper on 2012-002552-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-002552-16.